# US 2026/0083836 A1 · Modified coronavirus spike antigen protein and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083836 A1
- Document ID: US20260083836A1
- Status: Published application
- Kind: A1
- Application number: 18/872,553
- Filed: 2023-06-15
- Published: 2026-03-26
- Earliest claimed: 2022-06-16
- Assignees: RpexBio, Inc.
- Applicants: RpexBio, Inc.
- Inventors: Jong-Won OH; Hae-Gwang JUNG; Han Young SEO
- Web page: https://patentgrep.com/patent/US20260083836A1

## CPC

- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61K 39/12: Viral antigens
- A61P 31/14: for RNA viruses
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C07K 14/165: Coronaviridae, e.g. avian infectious bronchitis virus
- G01N 33/569: for microorganisms, e.g. protozoa, bacteria, viruses
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/575: {humoral response}
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

There is a modified coronavirus spike antigen protein and uses therefor. The spike antigen protein of coronavirus exhibits suppression of cell membrane fusion ability and improves safety by modifying two protein cleavage sites present in the coronavirus spike protein. In addition, inoculation with a vaccine having the antigen protein induces production of a large number of neutralizing antibodies to inhibit invasion of coronavirus into cells, thereby suppressing viral proliferation.

## Claims

### Claim 1

A spike antigen protein of coronavirus, in which a host protease cleavage site of the spike protein of coronavirus is modified.

### Claim 2 (depends on 1)

The spike antigen protein of claim 1, wherein the cleavage site is at least one selected from the cleavage sites of the furin protease in the sequences of the S1 and S2 domains of the spike protein of coronavirus and the cleavage site of the protease in the S2′ sequence thereof.

### Claim 3 (depends on 1)

The spike antigen protein of claim 1, wherein the coronavirus is at least one selected from the group consisting of severe acute respiratory syndrome coronavirus1 (SARS-CoV), severe acute respiratory syndrome coronavirus2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), human coronavirus 229E (HCoV-229E), and variants thereof.

### Claim 4 (depends on 2)

The spike antigen protein of claim 2, wherein the coronavirus is SARS-CoV-2, the furin protease cleavage site is at amino acid 685 of the spike protein, and the protease cleavage site in the S2′ sequence is at amino acid 815 of the spike protein.

### Claim 5 (depends on 4)

The spike antigen protein of claim 4, wherein amino acid 685 at the furin protease cleavage site is substituted with at least one amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, threonine, serine, cysteine, methionine, aspartic acid, asparagine, glutamic acid, glutamine, lysine, histidine, phenylalanine, tyrosine, tryptophan, and proline.

### Claim 6 (depends on 4)

The spike antigen protein of claim 4, wherein, at the cleavage site of the protease in the S2′ sequence, amino acid 815 of the spike protein is substituted with at least one amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, threonine, serine, cysteine, methionine, aspartic acid, asparagine, glutamic acid, glutamine, phenylalanine, tyrosine, tryptophan, and proline.

### Claim 7 (depends on 1)

The spike antigen protein of claim 1, wherein the modified spike antigen protein of coronavirus inhibits the generation of a free S1 domain.

### Claim 8 (depends on 1)

The spike antigen protein of claim 1, wherein the modified spike antigen protein of coronavirus inhibits cell membrane fusion.

### Claim 9 (depends on 1)

The spike antigen protein of claim 1, wherein the modified spike antigen protein of coronavirus inhibits intracellular entry of the virus or intracellular transfer of the viral genome.

### Claim 10 (depends on 1)

A recombinant vector for expressing an antigen protein of coronavirus, comprising a gene encoding the spike antigen protein of coronavirus of claim 1.

### Claim at position 11

11-17. (canceled)

### Claim 18 (depends on 1)

A method of preventing or treating coronavirus infection, comprising administering the spike antigen protein of coronavirus of claim 1 to an individual in need thereof.
